• Wed, December 18, 2024

by: The Motley Fool

Here's Where You'll Find the Best Stocks of 2025

That's the bad news. There's some good news, though. There are some investments you can make that will stand a good chance of making you a part owner of some of 2025's best stock performers. Here's a look at some of these investments.

by: The Globe and Mail

Better Quantum Computing Stock: Alphabet vs. IonQ

Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a "Double Down" stock recommendation for companies that they think are about to pop.

by: Kiplinger

Stock Market Today: Dow Dives 1,123 Points After Fed

The Dow Jones Industrial Average, on its longest losing streak since September 1974, was down 2.6% to 42,236. The S&P 500 declined 2.9.% to 5,872, while the Nasdaq Composite fell 3.6.% to 19,392.

by: Motley Fool Australia

2 ASX growth shares set to skyrocket in the next 12 months

Looking for ASX growth shares that could outperform the market in 2025? Here are two ideas that could be strong market-beaters.

by: Forbes

Beaten-Down Stocks Poised For A Comeback

Josef Lakonishok's investing strategy consists of buying underappreciated or ignored stocks at attractive prices. Here are stocks currently meeting his criteria.

by: MarketWatch

Stock Market Today: Dow trims gain after Fed cuts rates, signals fewer cut going forward

The Cboe Volatility Index, which trades under the ticker symbol VIX, was down 4% at slightly more than 15, according to FactSet data, at last check. The VIX was trading slightly below its 200-day moving average, based on FactSet data around midday Wednesday.

by: MSN

This Is How Much You'd Need To Invest In Apple Stock To Earn $100 per Month

Apple has been a tremendous long-term investment. The tech giant is up by roughly 30% year-to-date and has more than tripled over the past five years. While capital gains are a major selling point

by: The New York Times

Stocks Plunge as Fed Forecasts Fewer Rate Cuts Next Year

The Federal Reserve cut rates for a third time this year, but investors shuddered at revised forecasts suggesting only two cuts in 2025.

by: CNN

Fed set to cut rates for third and final time this year

The Federal Reserve is expected to cut interest rates again Wednesday, but President-elect Donald Trump's economic policies could thwart the central bank's progress on inflation.

by: Money Morning

Quantum Computing Primer: How It Works and the Top Stocks to Watch

Instead of using regular "bits" of data, quantum computers use qubits. Qubits can be 0, 1, or both at the same time, thanks to a property called superposition. This means a quantum computer can explore several solutions to a problem all at once.

by: moneycontrol.com

Firms close to IPOs are seeing good interest from rich Indians: Sandipan Roy

In an interview with Moneycontrol, Roy talks about how investing style of UNHIs have changed over the years, what innovative investment solutions they are looking at and risky trends in this space.

by: CNN-News18

Stocks To Watch: SBI, Infosys, IndusInd Bank, NITCO, VIP Industries And Others

IndusInd Bank: Reliance Nippon Life Insurance, a Reliance Capital (RCAP) subsidiary, is in talks with IndusInd Bank for a bancassurance partnership. Mauritius-based IndusInd International Holdings (IIHL), the parent of IndusInd Bank, recently won the bid to acquire RCAP and its subsidiaries as the acquisition process nears completion.

by: Seeking Alpha

Quantum Computing: Dangerously High Valuations

Quantum computing promises efficiency across sectors like cryptography and finance. Learn why cautious investment in QC stocks may be needed despite high growth.

by: The Motley Fool

Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose weight. A recent study found that it may not be Ozempic or Wegovy that's the best weight loss drug. Instead, that could come from Novo Nordisk's longtime rival, Eli Lilly ( LLY -0.17%).

by: Seeking Alpha

Marsh & McLennan: I Hold, And It's The Right Choice For Now

Marsh & McLennan is an A-rated business that hits its forecasted/stated targets 100% of the time. Read why I give MMC stock a Hold rating as of December 2024.
  • Thu, December 19, 2024

by: The Financial Express

Chennai Petro, ONGC, HPCL, Vedanta in list of top dividend yield stocks: Check list of key dividend paying stocks now

Explore top dividend yield stocks like Chennai Petro, ONGC, HPCL, and Vedanta. Discover their current market prices and yields now!

by: Reuters

US stocks face headwind from rising yields after Fed signals fewer rate cuts

The rally in U.S. stocks is encountering a fresh hurdle -- a potentially problematic rise in Treasury yields as the Federal Reserve signals fewer interest rate cuts for 2025.

by: MarketWatch

Stock Market Today: Dow ends down over 1,100 points after Fed lowers interest rates, signals fewer cuts in 2025

The Cboe Volatility Index, which trades under the ticker symbol VIX, was down 4% at slightly more than 15, according to FactSet data, at last check. The VIX was trading slightly below its 200-day moving average, based on FactSet data around midday Wednesday.

by: Indiatimes

Sensex Today | Stock Market LIVE Updates: Sensex slumps over 950 points, Nifty below 24K; all sectors bleed; Transrail Lighting IPO fully subscribed

by: The Daily Telegraph

'American tech stocks aren't working for me - how can I make big returns in five years?'

Would you like Kyle to rate your portfolio? Email money@telegraph.co.uk with the subject line: "Rate my portfolio". Please include a breakdown of your portfolio, your age and what your investing goals are. Full names will not be published. I'm looking for some help as to what...

by: Daily Express

Russia faces construction nightmare as stocks in country's biggest company plummet

Vladimir Putin is facing a construction nightmare as stocks in Russia's biggest construction group plummet. Bonds of the country's largest developer - the Samolet Group - have undergone a downward spiral through the summer and autumn.

by: Analytics Insight

Invest Wisely: Your Step-by-Step Guide on How to Invest in Stocks

A step-by-step guide Investing in stocks can seem daunting at first, but a solid understanding of the fundamentals can become a lucrati

by: Morningstar

The 60/40 Portfolio in 2025: What to Expect

In 2025, investors should pay attention to inflation. With high inflation, rates are going to rise. Tariffs in 2025 could have a real impact on inflation. As long as investors keep the time horizon in mind, the 60/40 portfolio is going to serve investors well over the long term.

by: moneycontrol.com

Super Fund Manager 2024: How this fund manager is winning the infra game with 47% return in a year

This is the third year of strong performance for the Invesco Mutual Fund, and it has consistently tried to stay ahead of market trends by leveraging domain knowledge and recognizing business cycles early,

by: Bloomberg L.P.

What's Next for Five of 2024's Most Dramatic Tech Stock Stories

Tech investors will remember 2024 as a year in which the artificial intelligence trade gained even more steam and giants like Nvidia Corp. and Meta Platforms Inc. carried the S&P 500 for the second time in a row.

by: The Motley Fool UK

2 FTSE 100 stocks that could outperform the index in 2025

Jon Smith flags up a couple of FTSE 100 stocks that have strong momentum right now and have beaten the index performance this year.

by: Business Insider

America is one big casino now

From elections and sports to stocks and meme coins, 2024 was the year gambling took over the American economy

by: The Globe and Mail

Investing in 2025 will be 'choose your own adventure': Desjardins Securities reveals its top TSX stock picks for the year ahead

Equity analysts at Desjardins Securities revealed their top stock picks for 2025 on Thursday, warning the outlook for the year ahead is cloudy and investors should proceed with caution after enjoying steep gains in 2024.

by: bnnbloomberg

S&P 500 Buyers Step in Ahead of Fed Meet Despite Narrow Breadth

While concern has grown in the past week that narrowing market breadth has tapped the brakes on the S&P 500 Index's blistering rally, it turns out that stock bulls are still stepping in to snap up shares ahead of the Federal Reserve's interest-rate decision.

by: Investing

S&P 500: Why Investing in the Benchmark Index Should Be Your Next Move

S&P 500, Microsoft Corporation, Apple Inc, Amazon.com Inc. Read Amarildi Riska's latest article on Investing.com

by: Indiatimes

Inventurus Knowledge Solutions Share Price Live: IKS shares list at 43% premium over IPO price

Shares of Inventurus Knowledge Solutions, a healthcare support services provider, are set to debut on the BSE and the NSE today. The IPO, priced in the range of ₹1,265 to ₹1,329 per share, was oversubscribed 52.

by: Yahoo

SoftwareOne announces deal to buy Norwegian rival Crayon

by: The Globe and Mail

Nvidia vs. Broadcom: Which Is the Better AI Chip Stock to Own in 2025?

While Nvidia is dominating the AI chip space, Broadcom is making inroads by helping customers develop custom AI chips. Its application-specific integrated circuits, or ASICs, are designed specifically for a customer's precise needs and can help with improved performance and more efficient power consumption.

by: Business Insider

Stocks tanked after the Fed signaled fewer rate cuts next year. Here's what analysts are saying.

The Federal Reserve cut interest rates on Wednesday but only projected two further cuts next year. Here's what analysts are saying about the news.

by: The Globe and Mail

2 Stocks Set to Dominate in 2025

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks » Its cutting-edge 3-nanometer (nm) chips are still increasing in demand, but it's already working on getting the ...

by: The Motley Fool

Got $250? 2 Healthcare Stocks to Buy and Hold Forever

That's why Novo Nordisk's shares are worth sticking with for good, and at about $108 apiece, investors can afford two of them with $250 and have some change left over.

by: The Motley Fool

Could This 1 Thing That's Happened Only 3 Times in the Past 67 Years Halt the S&P 500's Gains in 2025? Here's What History Says.

This year has been a fantastic one for stocks, from the moment the S&P 500 confirmed a bull market back in January to today, with the three major benchmarks heading for double-digit annual gains. The S&P 500 has climbed 27% this year, while the Nasdaq and the Dow Jones Industrial Average have advanced 34% and 15%, respectively.

by: Seeking Alpha

Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65

Dividend investing can provide reliable income and peace of mind in retirement. Check out dividend stocks ideal for retirees seeking steady cash flow and stability.

by: MSN

Is a stock market crash coming? And what should I do now?

Global investors are panicking about a new US stock market crash in the days or weeks ahead. Here's how I'm preparing for a possible slump. The post Is a stock market crash coming? And what should I do now?

by: The Motley Fool

3 Top Stocks That Could Double in 2025

Stocks are set to close out 2024 with one of their best performances this century.

by: MSN

Inside ExxonMobil's $30 Billion Plan to Build the Energy Company of the Future

ExxonMobil (NYSE: XOM) is the hands-down leader of today's carbon-powered world. The company is an industry-leading producer of hydrocarbons. It's also the most profitable company in the sector by a wide margin.

by: Seeking Alpha

Where Do Stocks Go From Here?

The S&P 500 is up about 30% this year (+28.07% through December 9) and has surged more than 75% since the depths of September 2022.

by: MSN

Stock Buybacks Outperform Dividends: Here's the Key Advantage

When investors consider the benefits of investing in a stock, they usually only consider the basic level of capital appreciation and dividend payouts. After all, this is what is largely covered in the mainstream financial media and what is talked about at the proverbial cocktail parties,

by: Seeking Alpha

How To Defend Against More 3% S&P 500 Down Days Like Wednesday

Learn how to assess market risk, protect against losses, and prepare for uncertain times with defensive strategies and insights from past crises.

by: MSN

Five key investing lessons for stock market investors from 2024

Key lessons included the importance of long-term strategies, avoiding impulsive decisions, and the potential for growth in India despite global uncertainties.

by: MSN

Better New Nasdaq-100 Buy: Palantir vs. MicroStrategy

The holidays have come early for a couple of this year's most-watched technology companies. I'm talking about Palantir Technologies (NASDAQ: PLTR) and MicroStrategy (NASDAQ: MSTR), software players that have soared more than 300% and 500%,

by: MSN

A 10% dividend yield? There could be significant potential here to earn a second income

by: MSN

Gianni Kovacevic: 3 Copper Stocks for Speculators, Watch These Metals Under Trump

Investor and author Gianni Kovacevic shared his thoughts on copper market dynamics, saying that while the long-term trend is up, speculators can create significant shorter-term prices moves. He also mentioned three copper companies he's interested in right now: CopperNico Metals (TSX:COPR,

Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose weight. A recent study found that it may not be Ozempic or Wegovy that's the best weight loss drug. Instead, that could come from Novo Nordisk's longtime rival, Eli Lilly ( LLY -0.17%).
The article from The Motley Fool discusses a head-to-head study comparing Ozempic, a popular weight loss drug, with Mounjaro, another weight loss medication. The study, which was published in the Journal of the American Medical Association (JAMA), found that Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) in terms of weight loss efficacy. Participants on Mounjaro lost significantly more weight than those on Ozempic, with the study highlighting Mounjaro's dual mechanism of action targeting both GLP-1 and GIP receptors, potentially explaining its superior results. This news has implications for investors and patients, as Mounjaro's manufacturer, Eli Lilly, could see increased market share and revenue, while Novo Nordisk, the maker of Ozempic, might face competitive pressure. The article also touches on the broader market dynamics, including the potential for Mounjaro to become a preferred choice for weight management, affecting stock prices and future pharmaceutical developments in the obesity treatment sector.

Read the Full The Motley Fool Article at:
https://www.fool.com/investing/2024/12/18/ozempic-dethroned-a-head-to-head-study-confirms-th/

Like: 👍